The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine
Overview
Authors
Affiliations
Background: Antigenically drifted A(H3N2) viruses circulated extensively during the 2014-2015 influenza season. Vaccine effectiveness (VE) was low and not significant among outpatients but in a hospitalized population was 43%. At least one study paradoxically observed increased A(H3N2) infection among those vaccinated 3 consecutive years.
Methods: We followed a cohort of 1341 individuals from 340 households. VE against laboratory-confirmed influenza was estimated. Hemagglutination-inhibition and neuraminidase-inhibition antibody titers were determined in subjects ≥13 years.
Results: Influenza A(H3N2) was identified in 166 (12%) individuals and B(Yamagata) in 34 (2%). VE against A(H3N2) was -3% (95% confidence interval [CI]: -55%, 32%) and similarly ineffective between age groups; increased risk of infection was not observed among those vaccinated in 2 or 3 previous years. VE against influenza B(Yamagata) was 57% (95% CI: -3%, 82%) but only significantly protective in children <9 years (87% [95% CI: 43%, 97%]). Less than 20% of older children and adults had ≥4-fold antibody titer rise against influenza A(H3N2) and B antigens following vaccination; responses were surprisingly similar for antigens included in the vaccine and those similar to circulating viruses. Antibody against A/Hong Kong/4801/14, similar to circulating 2014-2015 A(H3N2) viruses and included in the 2016-2017 vaccine, did not significantly predict protection.
Conclusions: Absence of VE against A(H3N2) was consistent with circulation of antigenically drifted viruses; however, generally limited antibody response following vaccination is concerning even in the context of antigenic mismatch. Although 2014-2015 vaccines were not effective in preventing A(H3N2) infection, no increased susceptibility was detected among the repeatedly vaccinated.
Rowe T, Fletcher A, Lange M, Hatta Y, Jasso G, Wentworth D mBio. 2025; 16(2):e0236124.
PMID: 39772665 PMC: 11796412. DOI: 10.1128/mbio.02361-24.
Rowe T, Fletcher A, Svoboda P, Pohl J, Hatta Y, Jasso G NPJ Vaccines. 2024; 9(1):199.
PMID: 39448628 PMC: 11502657. DOI: 10.1038/s41541-024-00973-2.
Rowe T, Davis W, Wentworth D, Ross T J Virol. 2024; 98(2):e0149423.
PMID: 38294251 PMC: 10878268. DOI: 10.1128/jvi.01494-23.
Voronina D, Shcheblyakov D, Favorskaya I, Esmagambetov I, Dzharullaeva A, Tukhvatulin A Viruses. 2022; 14(11).
PMID: 36366583 PMC: 9698552. DOI: 10.3390/v14112485.
Antiviral Peptides as Anti-Influenza Agents.
Agamennone M, Fantacuzzi M, Vivenzio G, Scala M, Campiglia P, Superti F Int J Mol Sci. 2022; 23(19).
PMID: 36232735 PMC: 9569631. DOI: 10.3390/ijms231911433.